Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI

Yuan Q, Deng D, Pan C, Wei T, Wu Z, Zhang B, Li S, Yin P and Shang D: Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy. Front Immunol. 13:9511372022. View Article : Google Scholar : PubMed/NCBI

Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI

Ribas A and Wolchok JD: Cancer immunotherapy using checkpoint blockade. Science. 359:1350–1355. 2018. View Article : Google Scholar : PubMed/NCBI

Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, Vishakha Behl T, Jha SK and Tang H: Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 22:1052023. View Article : Google Scholar : PubMed/NCBI

Morad G, Helmink BA, Sharma P and Wargo JA: Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 184:5309–5337. 2021. View Article : Google Scholar : PubMed/NCBI

O'Donnell JS, Teng MWL and Smyth MJ: Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 16:151–167. 2019. View Article : Google Scholar : PubMed/NCBI

Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane AF, et al: Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 6:865–871. 2020. View Article : Google Scholar : PubMed/NCBI

Zhang L, Feng J, Kuang T, Chai D, Qiu Z, Deng W, Dong K, Zhao K and Wang W: Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies. Int Immunopharmacol. 118:1100192023. View Article : Google Scholar : PubMed/NCBI

Zhao J, Li D, Xie S, Deng X, Wen X, Li J, Wu Z, Yang X, Li M, Tang Y, et al: Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis. Front Immunol. 13:10838402022. View Article : Google Scholar : PubMed/NCBI

Vergnenegre A and Chouaid C: Economic analyses of immune-checkpoint inhibitors to treat lung cancer. Expert Rev Pharmacoecon Outcomes Res. 21:365–371. 2021. View Article : Google Scholar : PubMed/NCBI

Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, Walsh AM, Baxi V, Pandya D, Baradet T, et al: Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 26:688–692. 2020. View Article : Google Scholar : PubMed/NCBI

Zhang L, Wang K, Kuang T, Deng W, Hu P and Wang W: Low geriatric nutritional risk index as a poor prognostic biomarker for immune checkpoint inhibitor treatment in solid cancer. Front Nutr. 10:12865832023. View Article : Google Scholar : PubMed/NCBI

Ren J, Wang A, Liu J and Yuan Q: Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma. Bioengineered. 12:4331–4348. 2021. View Article : Google Scholar : PubMed/NCBI

Havel JJ, Chowell D and Chan TA: The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 19:133–150. 2019. View Article : Google Scholar : PubMed/NCBI

Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030. 2003. View Article : Google Scholar : PubMed/NCBI

Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC: An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: A glasgow inflammation outcome study. Br J Cancer. 104:726–734. 2011. View Article : Google Scholar : PubMed/NCBI

Nagashima Y, Funahashi K, Kagami S, Ushigome M, Kaneko T, Miura Y, Yoshida K, Koda T and Kurihara A: Which preoperative immunonutritional index best predicts postoperative mortality after palliative surgery for malignant bowel obstruction in patients with late-stage cancer? A single-center study in Japan comparing the modified Glasgow prognostic score (mGPS), the prognostic nutritional index (PNI), and the controlling nutritional status (CONUT). Surg Today. 53:22–30. 2023. View Article : Google Scholar : PubMed/NCBI

Schuettfort VM, Gust K, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Rink M, Abufaraj M, Karakiewicz PI, et al: Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Minerva Urol Nephrol. 74:302–312. 2022. View Article : Google Scholar : PubMed/NCBI

Hsueh SW, Liu KH, Hung CY, Kuo YC, Tsai CY, Hsu JT, Hung YS, Tsang NM and Chou WC: Significance of the glasgow prognostic score in predicting the postoperative outcome of patients with stage III gastric cancer. J Clin Med. 8:14482019. View Article : Google Scholar : PubMed/NCBI

Vashist YK, Loos J, Dedow J, Tachezy M, Uzunoglu G, Kutup A, Yekebas EF and Izbicki JR: Glasgow prognostic score is a predictor of perioperative and long-term outcome in patients with only surgically treated esophageal cancer. Ann Surg Oncol. 18:1130–1138. 2011. View Article : Google Scholar : PubMed/NCBI

Yamada S, Fujii T, Yabusaki N, Murotani K, Iwata N, Kanda M, Tanaka C, Nakayama G, Sugimoto H, Koike M, et al: Clinical implication of inflammation-based prognostic score in pancreatic cancer: Glasgow prognostic score is the most reliable parameter. Medicine (Baltimore). 95:e35822016. View Article : Google Scholar : PubMed/NCBI

Shimoyama R, Imamura Y, Uryu K, Mase T, Ohtaki M, Ohtani K, Shiragami M, Fujimura Y, Hayashi M, Shinozaki N and Minami H: Inflammation-based prognostic markers in patients with advanced or recurrent gastric cancer treated with nivolumab: Tokushukai REAl-world Data project 02 (TREAD 02). Mol Clin Oncol. 21:902024. View Article : Google Scholar : PubMed/NCBI

Diker O and Olgun P: Association of the immune-inflammation-nutritional parameters with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. J Oncol Sci. 8:43–53. 2022. View Article : Google Scholar

Yamamoto Y, Matsuyama H, Matsumoto H, Sakano S, Fuji N, Oba K, Yamamoto M, Kamiryo Y, Hiragino T, Nagao K, et al: Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma. Jpn J Clin Oncol. 50:214–220. 2020. View Article : Google Scholar : PubMed/NCBI

Freitas C, Jacob M, Tavares N, Cruz-Martins N, Souto-Moura C, Araújo D, Novais-Bastos H, Santos V, Fernandes G, Magalhães A, et al: Modified glasgow prognostic score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents. Anticancer Drugs. 32:567–574. 2021. View Article : Google Scholar : PubMed/NCBI

Zhang L, Ma W, Qiu Z, Kuang T, Wang K, Hu B and Wang W: Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors. Front Immunol. 14:12199292023. View Article : Google Scholar : PubMed/NCBI

Zhang L, Li X, Wang K, Wu M, Liu W and Wang W: Prognostic impact of body composition in hepatocellular carcinoma patients with immunotherapy. Ann Med. 56:23950622024. View Article : Google Scholar : PubMed/NCBI

Zhang L, Xia Z, Li Z, Zhang J, Wang K and Wang W: Influence of body fat tissue on outcomes in patients undergoing hepatectomy or liver transplantation. Int J Surg. 111:1167–1181. 2024.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI

Ali WAS, Hui P, Ma Y, Wu Y, Zhang Y, Chen Y, Hong S, Yang Y, Huang Y, Zhao Y, et al: Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy. Ann Transl Med. 9:16392021. View Article : Google Scholar : PubMed/NCBI

Araki T, Tateishi K, Sonehara K, Hirota S, Komatsu M, Yamamoto M, Kanda S, Kuraishi H, Hanaoka M and Koizumi T: Clinical utility of the C-reactive protein:albumin ratio in non-small cell lung cancer patients treated with nivolumab. Thorac Cancer. 12:603–612. 2021. View Article : Google Scholar : PubMed/NCBI

Brown JT, Liu Y, Shabto JM, Martini D, Ravindranathan D, Hitron EE, Russler GA, Caulfield S, Yantorni L, Joshi SS, et al: Modified glasgow prognostic score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. J Immunother Cancer. 9:e0028512021. View Article : Google Scholar : PubMed/NCBI

Brown JT, Liu Y, Shabto JM, Martini DJ, Ravindranathan D, Hitron EE, Russler GA, Caulfield S, Yantorni LB, Joshi SS, et al: Baseline modified glasgow prognostic score associated with survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors. Oncologist. 26:397–405. 2021. View Article : Google Scholar : PubMed/NCBI

Chikuie N, Hamamoto T, Ueda T, Taruya T, Kono T, Furuie H, Ishino T and Takeno S: Baseline neutrophil-to-lymphocyte ratio and glasgow prognostic score are associated with clinical outcome in patients with recurrent or metastatic head and neck squamous cell carcinoma treated with nivolumab. Acta Med Okayama. 75:335–343. 2021.PubMed/NCBI

Fujiwara R, Takemura K, Fujiwara M, Yuasa T, Yasuoka S, Komai Y, Numao N, Yamamoto S and Yonese J: Modified glasgow prognostic score as a predictor of prognosis in metastatic renal cell carcinoma treated with nivolumab. Clin Genitourin Cancer. 19:e78–e83. 2021. View Article : Google Scholar : PubMed/NCBI

Imai H, Kishikawa T, Minemura H, Yamada Y, Ibe T, Yamaguchi O, Mouri A, Hamamoto Y, Kanazawa K, Kasai T, et al: Pretreatment glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer. Cancer Med. 10:6971–6984. 2021. View Article : Google Scholar : PubMed/NCBI

Kang HS, Shin AY, Yeo CD, Kim SK, Park CK, Kim JS, Kim SJ, Lee SH and Kim JW: Significance of glasgow prognostic scores in NSCLC patients treated with immunotherapy after platinum-based cytotoxic chemotherapy. In Vivo. 35:3423–3430. 2021. View Article : Google Scholar : PubMed/NCBI

Kasahara N, Sunaga N, Tsukagoshi Y, Miura Y, Sakurai R, Kitahara S, Yokobori T, Kaira K, Mogi A, Maeno T, et al: Post-treatment glasgow prognostic score predicts efficacy in advanced non-small-cell lung cancer treated with anti-PD1. Anticancer Res. 39:1455–1461. 2019. View Article : Google Scholar : PubMed/NCBI

Kasajima M, Igawa S, Manaka H, Yamada K, Akazawa Y, Manabe H, Yagami Y, Yamamoto H, Ito H, Kaizuka N, et al: The glasgow prognostic score predicts outcomes of pembrolizumab or atezolizumab monotherapy in patients with pretreated non-small cell lung cancer. Oncology. 101:69–76. 2023. View Article : Google Scholar : PubMed/NCBI

Kawakami H, Sunakawa Y, Inoue E, Matoba R, Noda K, Sato T, Suminaka C, Yamaki M, Sakamoto Y, Kawabata R, et al: Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial. Eur J Cancer. 184:10–20. 2023. View Article : Google Scholar : PubMed/NCBI

Kurosaki T, Kawakami H, Mitani S, Kawabata R, Takahama T, Nonagase Y, Fumita S, Ozaki T, Chiba Y, Tamura T and Nakagawa K: Glasgow prognostic score (GPS) and tumor response as biomarkers of nivolumab monotherapy in third- or later-line setting for advanced gastric cancer. In Vivo. 34:1921–1929. 2020. View Article : Google Scholar : PubMed/NCBI

Madeddu C, Busquets S, Donisi C, Lai E, Pretta A, López-Soriano FJ, Argilés JM, Scartozzi M and Macciò A: Effect of cancer-related cachexia and associated changes in nutritional status, inflammatory status, and muscle mass on immunotherapy efficacy and survival in patients with advanced non-small cell lung cancer. Cancers (Basel). 15:10762023. View Article : Google Scholar : PubMed/NCBI

Matsubara T, Takamori S, Haratake N, Toyozawa R, Miura N, Shimokawa M, Yamaguchi M, Seto T and Takenoyama M: The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab. J Thorac Dis. 12:1520–1528. 2020. View Article : Google Scholar : PubMed/NCBI

Matsuki T, Okamoto I, Fushimi C, Sawabe M, Kawakita D, Sato H, Tsukahara K, Kondo T, Okada T, Tada Y, et al: Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients. Cancer Med. 9:5015–5024. 2020. View Article : Google Scholar : PubMed/NCBI

Matsuo M, Yasumatsu R, Masuda M, Toh S, Wakasaki T, Hashimoto K, Jiromaru R, Manako T and Nakagawa T: Inflammation-based prognostic score as a prognostic biomarker in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with nivolumab therapy. In Vivo. 36:907–917. 2022. View Article : Google Scholar : PubMed/NCBI

Minichsdorfer C, Gleiss A, Aretin MB, Schmidinger M and Fuereder T: Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy. Ann Med. 54:1339–1349. 2022. View Article : Google Scholar : PubMed/NCBI

Minohara K, Matoba T, Kawakita D, Takano G, Oguri K, Murashima A, Nakai K, Iwaki S, Hojo W, Matsumura A, et al: Novel prognostic score for recurrent or metastatic head and neck cancer patients treated with nivolumab. Sci Rep. 11:169922021. View Article : Google Scholar : PubMed/NCBI

Mortensen REJ, Holmström MO, Lisle TL, Hasselby JP, Willemoe GL, Met Ö, Marie Svane I, Johansen J, Nielsen DL, Chen IM and Andersen MH: Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy. J Immunother Cancer. 11:e0064322023. View Article : Google Scholar : PubMed/NCBI

Namikawa T, Yokota K, Tanioka N, Fukudome I, Iwabu J, Munekage M, Uemura S, Maeda H, Kitagawa H, Kobayashi M and Hanazaki K: Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer. Surg Today. 50:1486–1495. 2020. View Article : Google Scholar : PubMed/NCBI

Niwa K, Kawakita D, Nagao T, Takahashi H, Saotome T, Okazaki M, Yamazaki K, Okamoto I, Hirai H, Saigusa N, et al: Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma. Sci Rep. 10:169882020. View Article : Google Scholar : PubMed/NCBI

Noguchi G, Nakaigawa N, Umemoto S, Kobayashi K, Shibata Y, Tsutsumi S, Yasui M, Ohtake S, Suzuki T, Osaka K, et al: C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma. Cancer Chemother Pharmacol. 86:75–85. 2020. View Article : Google Scholar : PubMed/NCBI

Ogura Y, Kataoka N, Kunimatsu Y, Tachibana Y, Sugimoto T, Tani N, Sato I, Hirose K, Kato D and Takeda T: Predictors of survival among Japanese patients receiving first-line chemoimmunotherapy for advanced non-small cell lung cancer. Thorac Cancer. 12:97–105. 2021. View Article : Google Scholar : PubMed/NCBI

Sakai D, Omori T, Fumita S, Fujita J, Kawabata R, Matsuyama J, Yasui H, Hirao M, Kawase T, Kishi K, et al: Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: A retrospective observational study. Int J Clin Oncol. 27:1154–1163. 2022. View Article : Google Scholar : PubMed/NCBI

Tada T, Kumada T, Hiraoka A, Kariyama K, Tani J, Hirooka M, Takaguchi K, Atsukawa M, Fukunishi S, Itobayashi E, et al: New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study. Cancer Med. 12:6980–6993. 2023. View Article : Google Scholar : PubMed/NCBI

Takamori S, Takada K, Shimokawa M, Matsubara T, Fujishita T, Ito K, Toyozawa R, Yamaguchi M, Okamoto T, Yoneshima Y, et al: Clinical utility of pretreatment glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer. 152:27–33. 2021. View Article : Google Scholar : PubMed/NCBI

Tanaka T, Yoshida T, Masuda K, Takeyasu Y, Shinno Y, Matsumoto Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N and Ohe Y: Prognostic role of modified glasgow prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies. Respir Investig. 61:74–81. 2023. View Article : Google Scholar : PubMed/NCBI

Tokuyama N, Takegawa N, Nishikawa M, Sakai A, Mimura T, Kushida S, Tsumura H, Yamamoto Y, Miki I and Tsuda M: Pretreatment glasgow prognostic score as a predictor of outcomes in nivolumab-treated patients with advanced gastric cancer. PLoS One. 16:e02476452021. View Article : Google Scholar : PubMed/NCBI

Ueki Y, Takahashi T, Ota H, Shodo R, Yamazaki K and Horii A: Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: Prognostic value of combined performance status and modified Glasgow prognostic score. Eur Arch Otorhinolaryngol. 277:2341–2347. 2020. View Article : Google Scholar : PubMed/NCBI

Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, et al: Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer. Front Oncol. 12:10807292023. View Article : Google Scholar : PubMed/NCBI

Yamamoto Y, Yatsuda J, Shimokawa M, Fuji N, Aoki A, Sakano S, Yamamoto M, Suga A, Tei Y, Yoshihiro S, et al: Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma. Int J Clin Oncol. 26:169–177. 2021. View Article : Google Scholar : PubMed/NCBI

Yang Z, Zhang D, Zeng H, Fu Y, Hu Z, Pan Y, Chen J, Wang J, Zhang Y, Zhou Z, et al: Inflammation-based scores predict responses to PD-1 inhibitor treatment in intrahepatic cholangiocarcinoma. J Inflamm Res. 15:5721–5731. 2022. View Article : Google Scholar : PubMed/NCBI

Zaitsu J, Yamashita Y, Ishikawa A, Saito A, Kagimoto A, Mimura T, Hirakawa T, Mito M, Fukuhara K, Senoo T, et al: Systemic inflammatory score predicts response and prognosis in patients with lung cancer treated with immunotherapy. Anticancer Res. 41:3673–3682. 2021. View Article : Google Scholar : PubMed/NCBI

Takegawa N, Hirabayashi T, Tanaka S, Nishikawa M, Tokuyama N, Mimura T, Kushida S, Tsumura H, Yamamoto Y, Miki I and Tsuda M: The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer. PLoS One. 18:e02853652023. View Article : Google Scholar : PubMed/NCBI

Tanaka K, Hirakawa H, Suzuki M, Higa T, Agena S, Hasegawa N, Kawakami J, Toyama M, Higa T, Kinjyo H, et al: Biomarkers for predicting anti-programmed cell death-1 antibody treatment effects in head and neck cancer. Curr Oncol. 30:5409–5424. 2023. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Chen S, Chen H and Li W: A comprehensive analysis of glasgow prognostic score (GPS)/the modified glasgow prognostic score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer. Cancer Med. 12:38–48. 2023. View Article : Google Scholar : PubMed/NCBI

Wu J, Wang H, Yang R, Liu D and Li W: Prognostic significance of the modified Glasgow Prognostic Score in NSCLC patients undergoing immune checkpoint inhibitor therapy: A meta-analysis. Front Oncol. 14:14498532024. View Article : Google Scholar : PubMed/NCBI

Wang H, Yang R, Cheng C, Wang S, Liu D and Li W: Prognostic value of the glasgow prognostic score in non-small cell lung cancer patients receiving immunotherapy: A meta-analysis. Nutr Cancer. 76:187–195. 2024. View Article : Google Scholar : PubMed/NCBI

Yao ZH, Tian GY, Yang SX, Wan YY, Kang YM, Liu QH, Yao F and Lin DJ: Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma. Tumour Biol. 35:6839–6845. 2014. View Article : Google Scholar : PubMed/NCBI

Gupta D and Lis CG: Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr J. 9:692010. View Article : Google Scholar : PubMed/NCBI

Miura K, Hamanaka K, Koizumi T, Kitaguchi Y, Terada Y, Nakamura D, Kumeda H, Agatsuma H, Hyogotani A, Kawakami S, et al: Clinical significance of preoperative serum albumin level for prognosis in surgically resected patients with non-small cell lung cancer: Comparative study of normal lung, emphysema, and pulmonary fibrosis. Lung Cancer. 111:88–95. 2017. View Article : Google Scholar : PubMed/NCBI

Yang J, Petersen CE, Ha CE and Bhagavan NV: Structural insights into human serum albumin-mediated prostaglandin catalysis. Protein Sci. 11:538–545. 2002. View Article : Google Scholar : PubMed/NCBI

China L, Maini A, Skene SS, Shabir Z, Sylvestre Y, Colas RA, Ly L, Becares Salles N, Belloti V, Dalli J, et al: Albumin counteracts immune-suppressive effects of lipid mediators in patients with advanced liver disease. Clin Gastroenterol Hepatol. 16:738–747.e7. 2018. View Article : Google Scholar : PubMed/NCBI

Choe WH and Baik SK: Prostaglandin E2-mediated immunosuppression and the role of albumin as its modulator. Hepatology. 61:1080–1082. 2015. View Article : Google Scholar : PubMed/NCBI

Arroyo V and Moreau R: Tying up PGE2 with albumin to relieve immunosuppression in cirrhosis. Nat Med. 20:467–469. 2014. View Article : Google Scholar : PubMed/NCBI

Du Clos TW and Mold C: C-reactive protein: An activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 30:261–277. 2004. View Article : Google Scholar : PubMed/NCBI

Nozoe T, Matsumata T and Sugimachi K: Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol. 23:263–266. 2000. View Article : Google Scholar : PubMed/NCBI

Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI

Abramovitch R, Marikovsky M, Meir G and Neeman M: Stimulation of tumour growth by wound-derived growth factors. Br J Cancer. 79:1392–1398. 1999. View Article : Google Scholar : PubMed/NCBI

Canna K, Hilmy M, McMillan DC, Smith GW, McKee RF, McArdle CS and McNicol AM: The relationship between tumour proliferative activity, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Colorectal Dis. 10:663–667. 2008. View Article : Google Scholar : PubMed/NCBI

Coffelt SB and de Visser KE: Cancer: Inflammation lights the way to metastasis. Nature. 507:48–49. 2014. View Article : Google Scholar : PubMed/NCBI

Bito R, Hino S, Baba A, Tanaka M, Watabe H and Kawabata H: Degradation of oxidative stress-induced denatured albumin in rat liver endothelial cells. Am J Physiol Cell Physiol. 289:C531–C542. 2005. View Article : Google Scholar : PubMed/NCBI

Wu J, Ding P, Wu H, Yang P, Guo H, Tian Y, Meng L and Zhao Q: Sarcopenia: Molecular regulatory network for loss of muscle mass and function. Front Nutr. 10:10372002023. View Article : Google Scholar : PubMed/NCBI

Condeelis J and Pollard JW: Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell. 124:263–266. 2006. View Article : Google Scholar : PubMed/NCBI

Ding P, Guo H, He X, Sun C, Lowe S, Bentley R, Zhou Q, Yang P, Tian Y, Liu Y, et al: Effect of skeletal muscle loss during neoadjuvant imatinib therapy on clinical outcomes in patients with locally advanced GIST. BMC Gastroenterol. 22:3992022. View Article : Google Scholar : PubMed/NCBI